Trials / Conditions / Secondary Myelodysplastic Syndrome

Secondary Myelodysplastic Syndrome

20 registered clinical trials studyying Secondary Myelodysplastic Syndrome — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome NCT05379166	Uma Borate	Phase 2
Recruiting	Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991	M.D. Anderson Cancer Center	Phase 1
Terminated	Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Pa NCT03333486	Roswell Park Cancer Institute	Phase 2
Completed	Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome NCT03359460	University of California, Davis	Phase 1
Active Not Recruiting	Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute M NCT02890329	National Cancer Institute (NCI)	Phase 1
Completed	High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in P NCT03128359	City of Hope Medical Center	Phase 2
Completed	Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome NCT02553941	Brian Jonas	Phase 1
Completed	Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodyspl NCT02485535	University of Chicago	Phase 1
Active Not Recruiting	Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Le NCT01885689	City of Hope Medical Center	Phase 2
Completed	Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant NCT01812252	Fred Hutchinson Cancer Center	Phase 2
Completed	Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloi NCT01757639	National Cancer Institute (NCI)	Phase 1
Completed	Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacit NCT01168219	National Cancer Institute (NCI)	Phase 2
Completed	Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586	National Cancer Institute (NCI)	Phase 1
Completed	Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leu NCT00588991	National Cancer Institute (NCI)	Phase 1
Completed	Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586	National Cancer Institute (NCI)	Phase 2
Completed	Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975	National Cancer Institute (NCI)	Phase 1
Completed	Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia NCT00357565	Masonic Cancer Center, University of Minnesota	Phase 2
Completed	Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blast NCT00217646	National Cancer Institute (NCI)	Phase 1
Completed	MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, o NCT00101179	National Cancer Institute (NCI)	Phase 1
Completed	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease i NCT00105001	Fred Hutchinson Cancer Center	Phase 2